DAVID SYMMES WILLIAMS, MD
Osteopathic Medicine at Straight St, Cincinnati, OH

7417026, Aug 26, 2008

Aug 12, 2004

10/918328

David A. Williams - Cincinnati OH, US
Yi Zheng - Cincinnati OH, US

Children's Hospital Medical Center - Cincinnati OH

A61K 38/00

514 12

Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve inhibition of both Rac1 and Rac2 GTPases to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. The subject's blood can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient and may in the future be utilized to repair a variety of non-hematopoietic tissues. Therefore, hematopoietic stem cells mobilized into a subject's peripheral blood by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. They can also be used for increasing white blood cell survival and for chemotherapy.

7915384, Mar 29, 2011

Jan 5, 2009

12/348762

Yi Zheng - Cincinnati OH, US
David A. Williams - Cincinnati OH, US

Children's Hospital Medical Center - Cincinnati OH

C07K 14/00, A01N 37/18

530350, 514 2

Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.

2006017, Aug 10, 2006

Jan 13, 2005

11/035019

Christof Kalle - Cincinnati OH, US
Lilith Reeves - Avon IN, US
David Williams - Cincinnati OH, US

G06Q 99/00

705002000, 705001000

Exemplary embodiments of the present invention provide three knowledge bases: (1) a clinical development plan (CDP) knowledge base for development of a molecular or cellular Phase I or II clinical trial; (2) a facility development plan (FDP) knowledge base for the economic and functional setup of translational laboratory, clean room production and cell handling facilities including the processes of planning, constructing and validating a facility for GCP testing and GMP manufacturing of products to support molecular and gene therapy clinical trials; and (3) a process development plan (PDP) knowledge base for development of manufacturing and analytic processes in support of Phase I or II clinical trials. The present invention also provides systems and methods associated with such knowledge bases.

7612080, Nov 3, 2009

Nov 18, 2005

11/283556

Yi Zheng - Cincinnati OH, US
Huzoor Akbar - Athens OH, US
David A. Williams - Cincinnati OH, US
Wieslaw Adam Mazur - Mason OH, US

Cincinnati Children's Hospital Medical Center - Cincinnati OH

A61K 31/506

514275

The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e. g. , in therapeutics, diagnostics, and as research tools.